The Germany-based company, which developed the first widely approved coronavirus shot together with U.S. partner Pfizer, aims to begin clinical trials for a "safe and highly effective malaria vaccine'' by the end of 2022.
For those in the medical sphere who've yet to have the chance to give a COVID-19 vaccine, this video by the Leslie Dan Faculty of Pharmacy at the University of Toronto provides a virtual demonstration on preparing the Pfizer-BioNTech vaccine.
Ottawa–A vaccine study in the United Kingdom reports that getting a dose of the Pfizer-BioNTech vaccine four weeks after a dose of Oxford-AstraZeneca produced a much stronger immune response than two doses of AstraZeneca.